Table 1

Clinical characteristics of 91 patients with interferon treatment–related type 1 diabetes

Sex (male)48 (53.4)
Age at onset of type 1 diabetes (years)56 (48–63)
Family history of type 1 diabetes0 (0)
Family history of type 2 diabetes23 (25.3)
Past history of type 2 diabetes14 (15.4)
Thirst69 (75.8)
Body weight loss56 (61.5)
Indication for IFN therapy
 Chronic HCV85 (93.4)
 Chronic hepatitis B1 (1.1)
 Chronic myelogenic leukemia2 (2.2)
 Renal cell carcinoma3 (3.3)
HCV genotype (n = 32)
 1a0 (0)
 1b26 (81.3)
 2a3 (9.4)
 2b3 (9.4)
Type of IFN
 IFNα10 (9.9)
 IFNα-2a11 (12.1)
 PegIFNα-2a8 (8.8)
 IFNα-2b21 (23.1)
 PegIFNα-2b38 (41.8)
 IFNβ3 (3.3)
Combination of ribavirin (from 2002)52 (72.2)
Mode of type 1 diabetes
 Fulminant onset5 (5.5)
 Acute onset74 (81.3)
 Slow onset7 (7.7)
 Others5 (5.5)
Period from recent IFN treatment to type 1 diabetes onset (years)0.68 (0.38–1.75)
Co-occurrence of autoimmune thyroid disease25 (27.5)
  • Data are n (%) or median (interquartile range). Family history of type 1 or type 2 diabetes was given for first-degree relatives. Body weight loss was defined as losing at least 5% of usual body weight within a few months. IFN, interferon; IFNα, natural IFNα.